Hu­man Longevi­ty makes a move to­ward Nas­daq with po­ten­tial SPAC deal, but noth­ing's fi­nal yet

An­ti-ag­ing com­pa­ny Hu­man Longevi­ty, found­ed by pi­o­neer­ing ge­nom­ic re­searcher Craig Ven­ter, is one step clos­er, po­ten­tial­ly, to be­com­ing a pub­lic com­pa­ny.

The start­up put out a press re­lease Mon­day af­ter­noon say­ing it has signed a “let­ter of in­tent” to re­verse merge with a SPAC run by for­mer Cred­it Su­isse CEO Tid­jane Thi­am, known as Free­dom Ac­qui­si­tion I Corp. If none of the SPAC in­vestors re­deem their shares and pull out at the float price of $10, Hu­man Longevi­ty will re­ceive $345 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER